Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

ATHE Stock  USD 4.08  0.11  2.63%   
About 55% of Alterity Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Alterity Therapeutics suggests that many traders are impartial. The current market sentiment, together with Alterity Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Alterity Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying

Read at benzinga.com
benzinga news
  

Alterity Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Alterity Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Alterity Therapeutics Fundamental Analysis

We analyze Alterity Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Gross Profit

Gross Profit Comparative Analysis

Alterity Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Alterity Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alterity Therapeutics stock to make a market-neutral strategy. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics with similar companies.

Peers

Alterity Therapeutics Related Equities

NBYNovaBay Pharmaceuticals   4.76   
0%
29.0%
PMVPPmv Pharmaceuticals   1.42   
0%
8.0%
SRZNSurrozen   1.25   
0%
7.0%
ANTXAN2 Therapeutics   0.88   
0%
5.0%
ANEBAnebulo Pharmaceuticals   0.79   
4.0%
0%
ADILAdial Pharmaceuticals   2.53   
15.0%
0%
QNRXQuoin Pharmaceuticals   3.13   
19.0%
0%
ARTLArtelo Biosciences   3.33   
20.0%
0%
TARAProtara Therapeutics   4.03   
25.0%
0%
ATXIAvenue Therapeutics   4.41   
27.0%
0%
HCWBHCW Biologics   5.13   
32.0%
0%
RVPHReviva Pharmaceuticals   7.01   
43.0%
0%
MNPRMonopar Therapeutics   10.58   
66.0%
0%
RNAZTranscode Therapeutics   15.99   
100.0%
0%

Complementary Tools for Alterity Stock analysis

When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Transaction History
View history of all your transactions and understand their impact on performance